You will need to have regular blood tests and check-ups during your treatment with hydroxycarbamide. The blood tests are important as a way of monitoring your treatment, and also to check that ...
Pfizer voluntarily withdraws all lots of sickle cell disease treatment Oxbryta from worldwide markets: New York Friday, September 27, 2024, 10:00 Hrs [IST] Pfizer Inc. announced t ...
Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease ...
Cost-effectiveness agency NICE has issued final draft guidance on Oxbryta (voxelotor) that clears the way for the use of the drug – with or without hydroxycarbamide – as an option for treating ...
We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...
We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...
NEW YORK, September 25, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell ...